Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa

Trial Profile

Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Naloxone (Primary)
  • Indications Bulimia nervosa
  • Focus Therapeutic Use
  • Sponsors Opiant Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2017 According to an Opiant Pharmaceuticals media release, completion of enrollment is expected by the end of Q2 2018.
    • 20 Mar 2017 According to an Opiant Pharmaceuticals media release, the company anticipates to report topline data from this study in the first half of 2018.
    • 20 Mar 2017 Status changed from not yet recruiting to recruiting, according to an Opiant Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top